DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Seidman A, Berry D, Cirrincione C et al.
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia group B protocol 9840.
J Clin Oncol 2008;
26: 1642-1649
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.